CytoCore's InPath System designed to upgrade Pap test

By Lisa Kerner

Erie, Pa., March 22 - CytoCore, Inc. said it has assembled four product components to form the InPath System NG, designed to improve various aspects of the traditional Pap test.

The components are CytoCore's e2 Collector, the CVX/GCI Assay, the AIPS automated microscopy platform and a new drug delivery system, according to a company news release.

"With these products, CytoCore has assembled a fully integrated system that uses state-of-the-art technology to significantly upgrade each aspect of the Pap test offering a very large increase in its capability, accuracy and reliability," director of basic research and head of CytoCore's medical advisory board George Gorodeski said in the release.

"In my opinion as a life long gynecological physician and researcher, the InPath System is truly unique, and it will make a major impact with the Pap test and the whole area of cervical cancer detection and treatment, thereby saving many lives both here and around the world."

The Food and Drug Administration-approved e2 Collector features a patented design to a better sampling of cells from the opening and into the cervical canal, the company said.

In the FDA trial, the Collector produced zero false positives and half the false negatives of the traditional spatula and brush.

CytoCore said its new CVX/GCI Assay is used to analyze the Pap test slide using a patent-pending combination of bio-markers to accurately identify cells that are turning, or are about to turn, cancerous. The assay turns target cells a fluorescent color for easier identification. Initial lab tests indicate the assay has accuracy rates from 87% to 100%.

The Automated Image Proteomic System (AIPS) is an automated image guided microscopy screening system that automatically scans slides for the presence of fluorescence and marked cells.

Lastly, the new patent-pending drug delivery system provides a therapeutic treatment option for early stage cervical lesions, delivering drug compounds in a controlled release manner.

Chicago-based CytoCore develops cancer screening systems used in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial and other cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.